Benzoxazole benzenesulfonamides are novel allosteric inhibitors of fructose-1,6-bisphosphatase with a distinct binding mode.

We have identified benzoxazole benzenesulfonamide 1 as a novel allosteric inhibitor of fructose-1,6-bisphosphatase (FBPase-1). X-ray crystallographic and biological studies of 1 indicate a distinct binding mode that recapitulates features of several previously reported FBPase-1 inhibitor classes.

[1]  M. Erion,et al.  Hypoglycaemic effect of AICAriboside in mice , 1996, Diabetologia.

[2]  H G Hers,et al.  Gluconeogenesis and related aspects of glycolysis. , 1983, Annual review of biochemistry.

[3]  J. Proietto,et al.  Impaired regulation of hepatic fructose-1,6-biphosphatase in the New Zealand Obese mouse: an acquired defect. , 1996, Metabolism: clinical and experimental.

[4]  R. Shi,et al.  Crystallization and preliminary crystallographic data of fructose-1,6-bisphosphatase from human muscle. , 2001, Acta crystallographica. Section D, Biological crystallography.

[5]  J. Mccormack,et al.  Pharmacological approaches to inhibit endogenous glucose production as a means of anti-diabetic therapy. , 2001, Current pharmaceutical design.

[6]  K. Manchester,et al.  A comparison of the effects of diabetes induced with either alloxan or streptozotocin and of starvation on the activities in rat liver of the key enzymes of gluconeogenesis. , 1970, The Biochemical journal.

[7]  M. Mansour,et al.  3-(2-carboxyethyl)-4,6-dichloro-1H-indole-2-carboxylic acid: an allosteric inhibitor of fructose-1,6-bisphosphatase at the AMP site. , 2003, Bioorganic & medicinal chemistry letters.

[8]  S. Pilkis,et al.  Isolation of a human liver fructose-1,6-bisphosphatase cDNA and expression of the protein in Escherichia coli. Role of ASP-118 and ASP-121 in catalysis. , 1993, The Journal of biological chemistry.

[9]  Bernd Meyer,et al.  Characterization of Ligand Binding by Saturation Transfer Difference NMR Spectroscopy. , 1999, Angewandte Chemie.

[10]  M. Erion,et al.  The allosteric site of human liver fructose-1,6-bisphosphatase. Analysis of six AMP site mutants based on the crystal structure. , 1995, The Journal of biological chemistry.

[11]  R G Shulman,et al.  Quantitation of hepatic glycogenolysis and gluconeogenesis in fasting humans with 13C NMR. , 1991, Science.

[12]  A. Baykov,et al.  A malachite green procedure for orthophosphate determination and its use in alkaline phosphatase-based enzyme immunoassay. , 1988, Analytical biochemistry.

[13]  M. J. Newman,et al.  Inhibition of Fructose-1,6-bisphosphatase by a New Class of Allosteric Effectors* , 2003, Journal of Biological Chemistry.

[14]  F. Capani,et al.  Predominant Role of Gluconeogenesis in Increased Hepatic Glucose Production in NIDDM , 1989, Diabetes.

[15]  S. Wright,et al.  Allosteric inhibition of fructose-1,6-bisphosphatase by anilinoquinazolines. , 2001, Bioorganic & medicinal chemistry letters.

[16]  R. Shulman,et al.  Increased rate of gluconeogenesis in type II diabetes mellitus. A 13C nuclear magnetic resonance study. , 1992, The Journal of clinical investigation.

[17]  R. DeFronzo.  PATHOGENESIS OF TYPE 2 DIABETES: METABOLIC AND MOLECULAR IMPLICATIONS FOR IDENTIFYING DIABETES GENES , 1997 .

[18]  M. Mansour,et al.  Anilinoquinazoline inhibitors of fructose 1,6-bisphosphatase bind at a novel allosteric site: synthesis, in vitro characterization, and X-ray crystallography. , 2002, Journal of medicinal chemistry.

[19]  Tao Jiang,et al.  MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes , 2005, Proceedings of the National Academy of Sciences of the United States of America.